MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and ra | ...

A novel IgG-guided elimination diet shows potential in reducing abdominal pain in patients with irritable bowel syndrome. Read now.

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

There have been hundreds of measles cases reported in the U.S. since the beginning of the year. Here's what you need to know ...

Wildfire smoke exposure acutely increased IL-13 expression in NK cells and was negatively associated with COVID-19 vaccine immunity.

FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to ...

Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.

Deutsche Bank says Biohaven’s (BHVN) competitor Immunovant (IMVT) reported topline data for FcRn antibody batoclimab in myasthenia gravis and ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.